創新醫療(002173.SZ):擬對建華醫院、康華醫院、福恬醫院各增資1000萬元
格隆匯11月18日丨創新醫療(002173.SZ)公佈,為了推動公司下屬醫院的供應鏈整合管理工作,公司同意鴻潤醫藥以貨幣的方式對建華醫院、康華醫院、福恬醫院各增資1000萬元。
公司此次同意鴻潤醫藥以貨幣的方式對建華醫院、康華醫院、福恬醫院各增資1000萬元,主要是為了推動公司下屬醫院的供應鏈整合管理工作,提升公司對下屬醫院進行集團化管理的能力,同時也有助於進一步增強下屬醫院的資本實力,符合公司經營發展的需要。此次增資完成後,建華醫院、康華醫院、福恬醫院仍為公司的子公司,不會對公司財務狀況和經營狀況產生不利影響,不存在損害公司及股東利益的情形。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.